Back

Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapy

Pandya, P.; Vendetti, F. P.; El-Ghoubaira, J. A.; Pathak, S.; Deppas, J. J.; Jones, R. E.; Columbus, A. V.; Zhang, Y.; Ivanov, D.; Huang, Z.; MacDonald, K. M.; Harding, S. M.; Buj, R.; Aird, K. M.; Beumer, J. H.; Sobol, R. W.; Bakkenist, C. J.

2024-04-05 cancer biology
10.1101/2024.04.04.588079 bioRxiv
Show abstract

DNA damage and cytoplasmic DNA induce type-1 interferon (IFN-1) and potentiate responses to immune checkpoint inhibitors. Our prior work found that inhibitors of the DNA damage response kinase ATR (ATRi) induce IFN-1 and deoxyuridine (dU) incorporation by DNA polymerases, akin to antimetabolites. Whether and how dU incorporation is required for ATRi-induced IFN-1 signaling is not known. Here, we show that ATRi-dependent IFN-1 responses require uracil DNA glycosylase (UNG)-initiated base excision repair and STING. Quantitative analyses of nine distinct nucleosides reveals that ATRi induce dU incorporation more rapidly in UNG wild-type than knockout cells, and that induction of IFN-1 is associated with futile cycles of repair. While ATRi induce similar numbers of micronuclei in UNG wild-type and knockout cells, dU containing micronuclei and cytoplasmic DNA are increased in knockout cells. Surprisingly, DNA fragments containing dU block STING-dependent induction of IFN-1, MHC-1, and PD-L1. Furthermore, UNG knockout sensitizes cells to IFN-{gamma} in vitro, and potentiates responses to anti-PD-L1 in resistant tumors in vivo. These data demonstrate an unexpected and specific role for dU-rich DNA in suppressing STING-dependent IFN-1 responses, and show that UNG-deficient tumors have a heightened response to immune checkpoint inhibitors. STATEMENT OF SIGNIFICANCEAntimetabolites disrupt nucleotide pools and increase dU incorporation by DNA polymerases. We show that unrepaired dU potentiates responses to checkpoint inhibitors in mouse models of cancer. Patients with low tumor UNG may respond to antimetabolites combined with checkpoint inhibitors, and patients with high tumor UNG may respond to UNG inhibitors combined with checkpoint inhibitors.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Cancer Research Communications
46 papers in training set
Top 0.1%
12.1%
2
Cancer Research
116 papers in training set
Top 0.1%
9.9%
3
Clinical Cancer Research
58 papers in training set
Top 0.1%
8.2%
4
Cell Reports
1338 papers in training set
Top 8%
6.2%
5
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 17%
4.1%
6
eLife
5422 papers in training set
Top 21%
4.1%
7
Cancers
200 papers in training set
Top 1%
3.9%
8
Nucleic Acids Research
1128 papers in training set
Top 6%
3.5%
50% of probability mass above
9
mBio
750 papers in training set
Top 5%
3.2%
10
Science Advances
1098 papers in training set
Top 11%
2.5%
11
Genetics
225 papers in training set
Top 2%
2.3%
12
Oncogene
76 papers in training set
Top 0.9%
1.8%
13
PLOS Genetics
756 papers in training set
Top 8%
1.8%
14
Molecular Cancer Research
42 papers in training set
Top 0.3%
1.7%
15
JCI Insight
241 papers in training set
Top 4%
1.7%
16
PLOS ONE
4510 papers in training set
Top 55%
1.7%
17
Genes & Development
90 papers in training set
Top 0.5%
1.7%
18
Molecular Cell
308 papers in training set
Top 7%
1.5%
19
NAR Cancer
36 papers in training set
Top 0.1%
1.5%
20
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.5%
21
Nature Communications
4913 papers in training set
Top 57%
1.2%
22
Scientific Reports
3102 papers in training set
Top 67%
1.2%
23
PLOS Pathogens
721 papers in training set
Top 8%
0.9%
24
Blood
67 papers in training set
Top 1%
0.9%
25
npj Precision Oncology
48 papers in training set
Top 1%
0.9%
26
EMBO reports
136 papers in training set
Top 6%
0.8%
27
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
28
BMC Cancer
52 papers in training set
Top 3%
0.7%
29
iScience
1063 papers in training set
Top 34%
0.7%
30
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.7%